Maharashtra’s Food and Drug Administration (FDA) conducted 2,902 inspections between June and August 2026, targeting drug manufacturers, pharmacies and other regulated establishments across the state, and took action against 880 establishments.
The crackdown led to 677 licence suspensions and 203 cancellations, while illegal medicines and cosmetics worth ₹11.41 crore were seized through 104 search-and-seizure operations. Officials also registered 20 FIRs and made 21 arrests.
The inspections uncovered concerns ranging from substandard and unauthorised medicines to sales without prescriptions, poor record-keeping and improper storage of temperature-sensitive drugs.
The intensified enforcement comes under FDA Commissioner Tukaram Mundhe, whose wider campaign has also focused on food safety and public health. While strict action is necessary to protect consumers, effective regulation must also ensure transparency, due process and sustained compliance rather than relying only on raids and punitive measures.
2,902 Inspections, 880 Actions
The Maharashtra FDA’s three-month enforcement drive offers a glimpse into the scale of regulatory violations being investigated across the state’s medicine supply chain. Of the 2,902 inspections, 607 were carried out at manufacturing establishments, while 2,295 targeted pharmaceutical sales outlets. Regulatory action followed against 140 manufacturing units and 740 sales establishments.
The inspections reportedly found several violations that could directly affect consumer safety. At manufacturing facilities, officials identified substandard or unauthorised medicines, gaps in quality-control procedures, incomplete production records and discrepancies between documented and actual quantities of ingredients. Some establishments also lacked proper vendor-audit records and sterilisation documentation.
At pharmacies and sales outlets, inspectors found medicines being sold without the supervision of registered pharmacists, missing or incomplete billing details and instances of scheduled medicines being supplied without the required prescriptions. Expired medicines were also reportedly found alongside saleable stock instead of being kept separately in designated “Not for Sale” areas.
Another serious concern involved temperature-sensitive medicines, including insulin and vaccines. Officials found instances where products requiring controlled storage were allegedly kept at ambient temperatures rather than the prescribed 2°C-8°C range. Such lapses can potentially affect medicine quality even when the product itself was legally manufactured.
₹11.41 Crore Stock Seized
The enforcement drive also resulted in the seizure of illegal medicines and cosmetics valued at ₹11.41 crore. The FDA carried out 104 search-and-seizure operations, leading to 20 FIRs and 21 arrests. The department has also reported a notable rise in complaints and enforcement activity during the period.
The action comes as Commissioner Tukaram Mundhe has adopted a more visible enforcement approach across the FDA. His campaign has extended beyond pharmaceutical establishments to restaurants, food manufacturers, dairies, street vendors and other businesses dealing directly with public health.
Mundhe’s approach has attracted significant attention on social media, where videos and reports of inspections have circulated widely. He has consistently argued that businesses operating in regulated sectors must follow the law and that public health cannot be compromised for commercial convenience.
The FDA’s crackdown therefore involves more than simply confiscating illegal products. It highlights the importance of maintaining a reliable chain of accountability — from manufacturing and quality testing to transportation, storage, prescription and final sale. For consumers, these checks can be crucial because they often have no way of independently verifying whether a medicine has been stored correctly or whether its supply records are complete.
Beyond Medicines: Wider FDA Drive
The pharmaceutical inspections form part of a broader regulatory push under Mundhe. The commissioner has also intensified food-safety inspections across Maharashtra, with raids targeting establishments suspected of violating safety standards.
The wider campaign has gained public visibility, particularly after inspections of food businesses were shared online. The FDA has also moved towards a more systematic enforcement model around festivals, when demand for sweets, dairy products, edible oils and other food items rises sharply.
This wider focus reflects a simple public-health principle: prevention and compliance are preferable to discovering problems only after consumers are affected. At the same time, enforcement agencies face the challenge of ensuring that strong action is supported by transparent procedures, accurate documentation and opportunities for establishments to respond to allegations.
For the pharmaceutical sector in particular, this balance is important. Suspending or cancelling licences can have serious consequences for businesses and employees, but allowing unsafe or unauthorised medicines to circulate can have far more serious consequences for patients.
The latest figures also underline why regular inspections matter. Problems such as poor temperature control, missing batch information, inadequate records and unauthorised sales may appear administrative on paper, but they can directly influence whether patients receive medicines that are safe, effective and properly traceable.
Experts Call For Stronger Compliance Measures
Experts in pharmaceutical regulation and public health say inspections and punitive action are important, but lasting improvements require regular monitoring, stronger internal quality controls and better compliance training across the medicine supply chain.
They stress that manufacturers and pharmacies should maintain accurate records, follow prescribed storage conditions, ensure proper dispensing of scheduled medicines and immediately segregate expired or damaged stock.
Experts also caution that enforcement should be consistent, transparent and evidence-based, giving compliant businesses clarity while taking firm action against deliberate or repeated violations.
For consumers, they recommend purchasing medicines only from licensed pharmacies, checking packaging, expiry dates and batch details, and consulting a qualified healthcare professional rather than self-medicating.
The Logical Indian’s Perspective
A strong regulatory system should ultimately be about protecting people, not simply punishing businesses. Maharashtra’s FDA deserves recognition for stepping up inspections and acting against establishments where serious violations are found. At the same time, enforcement should remain transparent, evidence-based and consistent, with businesses given a fair opportunity to rectify genuine shortcomings while deliberate or dangerous violations face firm consequences.
Public health works best when regulators, manufacturers, pharmacists and consumers understand that they are part of the same ecosystem. Businesses need to treat safety standards as a responsibility rather than a burden, while authorities must ensure that enforcement remains accountable and proportionate. The larger goal should be a system where people can trust that the medicines they buy are genuine, properly stored and safe to use.
